Case-Based Learning: Delayed Immune-Mediated Toxicity After Cell Therapy

Abstract

Delayed immune-mediated toxicity is an increasingly recognized complication following cell therapy, particularly with the expanding use of chimeric antigen receptor (CAR) T-cell therapies and other adoptive immune cell approaches. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management, and recent advances in the recognition and treatment of delayed immune-mediated toxicities after cell therapy. A case-based framework is used to highlight clinical decision-making points, with emphasis on guideline-driven practice and translational research findings. The review provides clinicians with up-to-date, evidence-based tools to improve outcomes, reduce morbidity, and inform future directions in cell therapy toxicity management.

Introduction

Cell-based therapies, notably CAR T-cell therapy and other engineered immune cell platforms, have revolutionized the management of hematological malignancies and are increasingly explored in solid tumors and autoimmune diseases. While early toxicities such as cytokine release syndrome (CRS) and neurotoxicity are well-characterized, delayed immune-mediated toxicities (DIMTs) are emerging as a significant clinical challenge. DIMTs may manifest weeks to months post-infusion, with diverse presentations that complicate diagnosis and management. Understanding the epidemiology, underlying mechanisms, and evidence-based management strategies is critical for healthcare professionals involved in cell therapy care.

Epidemiology / Disease Burden

The incidence of delayed immune-mediated toxicity varies depending on cell therapy product, indication, and patient-specific factors. Recent multicenter studies report DIMT rates ranging from 10% to 25% in CAR T-cell recipients, with higher rates observed in specific products targeting BCMA and CD22. The spectrum of DIMTs includes delayed cytopenias, autoimmune cytopenias, secondary hemophagocytic lymphohistiocytosis (sHLH), late-onset neurotoxicity, and organ-specific immune-mediated damage (e.g., myocarditis, nephritis). As cell therapy indications expand, the burden of DIMTs is expected to rise, underscoring the need for vigilance in long-term follow-up protocols and registry-based epidemiological studies.

Pathophysiology

DIMTs are driven by persistent or reactivated immune effector cells, leading to aberrant immune activation against host tissues. Proposed mechanisms include prolonged cytokine release, off-target effects of engineered receptors, and breakdown of peripheral tolerance. Pro-inflammatory cytokines such as IFN-γ, IL-6, and TNF-α have been implicated in sustaining immune activation. In some cases, epitope spreading and bystander activation contribute to autoimmunity. Furthermore, the persistence of CAR T-cells or other engineered cells in circulation can lead to chronic immune dysregulation. Recent preclinical studies highlight the role of T-cell exhaustion reversal and regulatory T-cell (Treg) depletion in potentiating DIMTs.

Risk Factors

Identifying patients at risk for DIMTs is essential for preventive strategies. Risk factors include high tumor burden at baseline, prior episodes of early CRS or neurotoxicity, use of lymphodepleting regimens, pre-existing autoimmune disorders, and specific CAR constructs with high in vivo persistence. Genetic predispositions, such as HLA haplotypes favoring autoimmunity, may also contribute. Patients with robust expansion of CAR T-cells or a history of stem cell transplantation are at heightened risk. Understanding these predictors allows for individualized monitoring and early intervention.

Clinical Features

DIMTs present heterogeneously, often weeks to months after cell infusion. Common manifestations include prolonged cytopenias (lymphopenia, neutropenia, thrombocytopenia), autoimmune cytopenias (e.g., autoimmune hemolytic anemia), late-onset neurotoxicity (cognitive changes, seizures), and organ-specific inflammation (myocarditis, nephritis, pneumonitis). Systemic symptoms such as fever, fatigue, and malaise may precede more specific findings. Case-based learning reveals the importance of a high index of suspicion and careful longitudinal assessment, as symptoms may overlap with infection, relapse, or drug toxicities.

Diagnosis

Diagnosis of DIMTs requires a systematic approach, integrating clinical, laboratory, and imaging findings. Laboratory evaluation includes complete blood counts, inflammatory markers (CRP, ferritin), cytokine panels, and organ-specific tests (e.g., troponin for myocarditis, creatinine for nephritis). Imaging studies, such as MRI for neurotoxicity or echocardiography for myocarditis, are often essential. Bone marrow biopsy may be warranted in cases of persistent cytopenia to exclude relapse or marrow failure. Flow cytometry and molecular studies can assess CAR T-cell persistence and expansion. Exclusion of infectious and malignant etiologies is paramount.

Treatment & Management

Management of DIMTs is guided by severity and organ involvement. Mild cases may respond to supportive care and close monitoring. Moderate to severe cases often require immunosuppressive therapy, such as corticosteroids, intravenous immunoglobulin (IVIG), or targeted agents like tocilizumab (IL-6 receptor antagonist) and anakinra (IL-1 receptor antagonist). For refractory cases, plasmapheresis or cytotoxic immunosuppression (e.g., rituximab, cyclophosphamide) may be indicated. It is critical to balance immunosuppression with maintaining anti-tumor efficacy. Multidisciplinary collaboration, including hematology, neurology, cardiology, and rheumatology, optimizes patient outcomes.

Recent Advances / Emerging Therapies

Emerging strategies focus on minimizing DIMTs without compromising therapeutic benefits. Novel CAR designs incorporating suicide switches or tunable expression systems allow for controlled depletion of effector cells in cases of severe toxicity. Bispecific antibodies and universal CAR platforms are under investigation to reduce off-target effects. Biomarker-driven risk stratification and real-time monitoring of cytokine profiles are being integrated into clinical trials. In addition, research on adoptive regulatory T-cell infusion and checkpoint blockade modulation holds promise for mitigating autoimmunity post-therapy. These advances represent a paradigm shift towards personalized toxicity management.

Guideline Recommendations

Recent consensus guidelines from the American Society for Transplantation and Cellular Therapy (ASTCT) and European Society for Blood and Marrow Transplantation (EBMT) recommend routine long-term monitoring for DIMTs in all cell therapy recipients. Structured follow-up should include serial laboratory assessments, neurocognitive evaluation, and organ function monitoring. Early consultation with subspecialists is advised for any new or worsening symptoms. Guidelines emphasize prompt initiation of immunosuppressive therapy for moderate to severe cases and consideration of clinical trial enrollment for novel interventions. Education of patients and caregivers regarding delayed toxicity risks is essential to ensure timely reporting and intervention.

Conclusion

Delayed immune-mediated toxicity is a complex, multifaceted complication of cell therapy that poses significant diagnostic and therapeutic challenges. Recognition of risk factors, timely diagnosis, and evidence-based management are critical to improving patient outcomes. Ongoing research into the mechanisms and mitigation of DIMTs promises to enhance the safety and efficacy of cell-based therapies. Multidisciplinary care, adherence to evolving guidelines, and patient-centered surveillance are cornerstones of effective clinical practice in this rapidly advancing field.